Science for New Life
Guangzhou Vbio Pharma Co., Ltd. (here after as VBIO) is a certified high-tech enterprise and a global leader in human and animal reproductive biologics (including IVF and fertility) founded in 2015. Backed by elite protein biologics experts from MSD, Yale University, UC Berkeley, Washington University and University of Toronto, our 200+ team specializes in the R&D, manufacturing, and sales of APIs, formulations, veterinary drugs, intimate health, and personal care products. With RMB 65 million in registered capital, VBIO delivers world-class innovation from our Guangzhou Economic and Technological Development Zone base.
Long‑acting Recombinant Follitropin Compound Preparation. It significantly improves the oestrus and mating rate as well as the overall conception rate of sows, shortens non‑productive days, and its performance meets or exceeds that of comparable imported products.
Class‑I New Veterinary Drug, a recombinant protein produced by genetic engineering and mammalian cell expression. It is applied for estrus induction and batch production management in sows. It features stable quality, high safety, with potency complying with the standards of European Pharmacopoeia.
All products available as API raw materials or finished formulations. Custom specifications and packaging supported. Veterinary products support OEM/ODM services.